Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Improved process conditions for increasing expression of MHC class II protein from a stable Drosophila S2 cell line.

Shen X, Dojcinovic D, Baldi L, Hacker DL, Luescher IF, Wurm FM.

Biotechnol Lett. 2018 Jan;40(1):85-92. doi: 10.1007/s10529-017-2440-0. Epub 2017 Oct 9.

PMID:
28993910
2.

Current tools for predicting cancer-specific T cell immunity.

Gfeller D, Bassani-Sternberg M, Schmidt J, Luescher IF.

Oncoimmunology. 2016 Apr 25;5(7):e1177691. doi: 10.1080/2162402X.2016.1177691. eCollection 2016 Jul. Review.

3.

CD8 engineered cytotoxic T cells reprogram melanoma tumor environment.

Leignadier J, Favre S, Luther SA, Luescher IF.

Oncoimmunology. 2015 Sep 11;5(3):e1086861. eCollection 2016 Mar.

4.

Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses.

Matsuzaki J, Tsuji T, Luescher IF, Shiku H, Mineno J, Okamoto S, Old LJ, Shrikant P, Gnjatic S, Odunsi K.

Sci Rep. 2015 Oct 8;5:14896. doi: 10.1038/srep14896.

5.

MHC/Peptide-Specific Interaction of the Humoral Immune System: A New Category of Antibodies.

Held G, Luescher IF, Neumann F, Papaioannou C, Schirrmann T, Sester M, Smola S, Pfreundschuh M.

J Immunol. 2015 Nov 1;195(9):4210-7. doi: 10.4049/jimmunol.1402902. Epub 2015 Sep 28.

6.

Duality of the murine CD8 compartment.

Genolet R, Leignadier J, Østerås M, Farinelli L, Stevenson BJ, Luescher IF.

Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):E1007-15. doi: 10.1073/pnas.1317847111. Epub 2014 Mar 4.

7.

PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.

Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Moschos S, Wang H, Guillaume P, Luescher IF, Krieg A, Anderson AC, Kuchroo VK, Zarour HM.

Cancer Res. 2014 Feb 15;74(4):1045-55. doi: 10.1158/0008-5472.CAN-13-2908. Epub 2013 Dec 16.

8.

CTLA-4 controls the thymic development of both conventional and regulatory T cells through modulation of the TCR repertoire.

Verhagen J, Genolet R, Britton GJ, Stevenson BJ, Sabatos-Peyton CA, Dyson J, Luescher IF, Wraith DC.

Proc Natl Acad Sci U S A. 2013 Jan 15;110(3):E221-30. doi: 10.1073/pnas.1208573110. Epub 2012 Dec 24.

9.

Highly diverse TCRα chain repertoire of pre-immune CD8⁺ T cells reveals new insights in gene recombination.

Genolet R, Stevenson BJ, Farinelli L, Osterås M, Luescher IF.

EMBO J. 2012 Nov 5;31(21):4247-8. doi: 10.1038/emboj.2012.277. No abstract available.

10.

An optimized method for establishing high purity murine CD8+ T cell cultures.

Zanker D, Xiao K, Oveissi S, Guillaume P, Luescher IF, Chen W.

J Immunol Methods. 2013 Jan 31;387(1-2):173-80. doi: 10.1016/j.jim.2012.10.012. Epub 2012 Oct 22.

PMID:
23098837
11.

Cholesterol and sphingomyelin drive ligand-independent T-cell antigen receptor nanoclustering.

Molnár E, Swamy M, Holzer M, Beck-García K, Worch R, Thiele C, Guigas G, Boye K, Luescher IF, Schwille P, Schubert R, Schamel WW.

J Biol Chem. 2012 Dec 14;287(51):42664-74. doi: 10.1074/jbc.M112.386045. Epub 2012 Oct 22.

12.

The T-cell receptor is not hardwired to engage MHC ligands.

Holland SJ, Bartok I, Attaf M, Genolet R, Luescher IF, Kotsiou E, Richard A, Wang E, White M, Coe DJ, Chai JG, Ferreira C, Dyson J.

Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):E3111-8. doi: 10.1073/pnas.1210882109. Epub 2012 Oct 17.

13.

A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen.

Zhao RY, Mifsud NA, Xiao K, Chan KF, Oveissi S, Jackson HM, Dimopoulos N, Guillaume P, Knights AJ, Lowen T, Robson NC, Russell SE, Scotet E, Davis ID, Maraskovsky E, Cebon J, Luescher IF, Chen W.

PLoS One. 2012;7(9):e44707. doi: 10.1371/journal.pone.0044707. Epub 2012 Sep 6.

14.

KAP1 regulates gene networks controlling T-cell development and responsiveness.

Santoni de Sio FR, Barde I, Offner S, Kapopoulou A, Corsinotti A, Bojkowska K, Genolet R, Thomas JH, Luescher IF, Pinschewer D, Harris N, Trono D.

FASEB J. 2012 Nov;26(11):4561-75. doi: 10.1096/fj.12-206177. Epub 2012 Aug 7.

15.

TSLP promotes influenza-specific CD8+ T-cell responses by augmenting local inflammatory dendritic cell function.

Yadava K, Sichelstiel A, Luescher IF, Nicod LP, Harris NL, Marsland BJ.

Mucosal Immunol. 2013 Jan;6(1):83-92. doi: 10.1038/mi.2012.50. Epub 2012 Jul 18.

16.

Highly diverse TCRα chain repertoire of pre-immune CD8⁺ T cells reveals new insights in gene recombination.

Genolet R, Stevenson BJ, Farinelli L, Osterås M, Luescher IF.

EMBO J. 2012 Apr 4;31(7):1666-78. doi: 10.1038/emboj.2012.48. Epub 2012 Feb 28.

17.

CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.

Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Olive D, Kuchroo V, Zarour HM.

Cancer Res. 2012 Feb 15;72(4):887-96. doi: 10.1158/0008-5472.CAN-11-2637. Epub 2011 Dec 28.

18.

Reversible major histocompatibility complex I-peptide multimers containing Ni(2+)-nitrilotriacetic acid peptides and histidine tags improve analysis and sorting of CD8(+) T cells.

Schmidt J, Guillaume P, Irving M, Baumgaertner P, Speiser D, Luescher IF.

J Biol Chem. 2011 Dec 2;286(48):41723-35. doi: 10.1074/jbc.M111.283127. Epub 2011 Oct 11.

19.

Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells.

Baumgaertner P, Jandus C, Rivals JP, Derré L, Lövgren T, Baitsch L, Guillaume P, Luescher IF, Berthod G, Matter M, Rufer N, Michielin O, Speiser DE.

Int J Cancer. 2012 Jun 1;130(11):2607-17. doi: 10.1002/ijc.26297. Epub 2011 Aug 24.

20.

Basal and antigen-induced exposure of the proline-rich sequence in CD3ε.

de la Cruz J, Kruger T, Parks CA, Silge RL, van Oers NS, Luescher IF, Schrum AG, Gil D.

J Immunol. 2011 Feb 15;186(4):2282-90. doi: 10.4049/jimmunol.1003225. Epub 2011 Jan 12.

21.

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.

Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM.

J Exp Med. 2010 Sep 27;207(10):2175-86. doi: 10.1084/jem.20100637. Epub 2010 Sep 6.

22.

Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.

Johannsen A, Genolet R, Legler DF, Luther SA, Luescher IF.

J Immunol. 2010 Sep 15;185(6):3445-55. doi: 10.4049/jimmunol.1001397. Epub 2010 Aug 23.

23.

Novel soluble HLA-A2/MELAN-A complexes selectively stain a differentiation defective subpopulation of CD8+ T cells in patients with melanoma.

Guillaume P, Baumgaertner P, Neff L, Rufer N, Wettstein P, Speiser DE, Luescher IF.

Int J Cancer. 2010 Aug 15;127(4):910-23. doi: 10.1002/ijc.25099.

24.

Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.

Jandus C, Bioley G, Dojcinovic D, Derré L, Baitsch L, Wieckowski S, Rufer N, Kwok WW, Tiercy JM, Luescher IF, Speiser DE, Romero P.

Cancer Res. 2009 Oct 15;69(20):8085-93. doi: 10.1158/0008-5472.CAN-09-2226. Epub 2009 Oct 6.

25.
26.

Fab antibodies capable of blocking T cells by competitive binding have the identical specificity but a higher affinity to the MHC-peptide-complex than the T cell receptor.

Neumann F, Sturm C, Hülsmeyer M, Dauth N, Guillaume P, Luescher IF, Pfreundschuh M, Held G.

Immunol Lett. 2009 Aug 15;125(2):86-92. doi: 10.1016/j.imlet.2009.06.002. Epub 2009 Jun 12.

PMID:
19524620
27.

PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.

Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, Guillaume P, Luescher IF, Sander C, Ferrone S, Kirkwood JM, Zarour HM.

J Immunol. 2009 May 1;182(9):5240-9. doi: 10.4049/jimmunol.0803245.

28.

Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4.

Klein O, Ebert LM, Nicholaou T, Browning J, Russell SE, Zuber M, Jackson HM, Dimopoulos N, Tan BS, Hoos A, Luescher IF, Davis ID, Chen W, Cebon J.

Clin Cancer Res. 2009 Apr 1;15(7):2507-13. doi: 10.1158/1078-0432.CCR-08-2424. Epub 2009 Mar 24.

29.

A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.

Ebert LM, Liu YC, Clements CS, Robson NC, Jackson HM, Markby JL, Dimopoulos N, Tan BS, Luescher IF, Davis ID, Rossjohn J, Cebon J, Purcell AW, Chen W.

Cancer Res. 2009 Feb 1;69(3):1046-54. doi: 10.1158/0008-5472.CAN-08-2926. Epub 2009 Jan 27. Erratum in: Cancer Res. 2009 May 15;69(10):4553.

30.

CD8beta knockout mice mount normal anti-viral CD8+ T cell responses--but why?

Angelov GS, Guillaume P, Luescher IF.

Int Immunol. 2009 Feb;21(2):123-35. doi: 10.1093/intimm/dxn130. Epub 2008 Dec 15.

PMID:
19088062
31.

Combining MHC tetramer and intracellular cytokine staining for CD8(+) T cells to reveal antigenic epitopes naturally presented on tumor cells.

Dimopoulos N, Jackson HM, Ebert L, Guillaume P, Luescher IF, Ritter G, Chen W.

J Immunol Methods. 2009 Jan 1;340(1):90-4. doi: 10.1016/j.jim.2008.09.023. Epub 2008 Oct 26.

PMID:
18957296
32.

Increased mobility of major histocompatibility complex I-peptide complexes decreases the sensitivity of antigen recognition.

Segura JM, Guillaume P, Mark S, Dojcinovic D, Johannsen A, Bosshard G, Angelov G, Legler DF, Vogel H, Luescher IF.

J Biol Chem. 2008 Aug 29;283(35):24254-63. doi: 10.1074/jbc.M803549200. Epub 2008 Jun 25.

33.

The T cell receptor's alpha-chain connecting peptide motif promotes close approximation of the CD8 coreceptor allowing efficient signal initiation.

Mallaun M, Naeher D, Daniels MA, Yachi PP, Hausmann B, Luescher IF, Gascoigne NR, Palmer E.

J Immunol. 2008 Jun 15;180(12):8211-21.

34.

Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes.

Demotte N, Stroobant V, Courtoy PJ, Van Der Smissen P, Colau D, Luescher IF, Hivroz C, Nicaise J, Squifflet JL, Mourad M, Godelaine D, Boon T, van der Bruggen P.

Immunity. 2008 Mar;28(3):414-24. doi: 10.1016/j.immuni.2008.01.011.

35.

IL-12 controls cytotoxicity of a novel subset of self-antigen-specific human CD28+ cytolytic T cells.

Barbey C, Baumgaertner P, Devevre E, Rubio-Godoy V, Derre L, Bricard G, Guillaume P, Luescher IF, Liénard D, Cerottini JC, Romero P, Rufer N, Speiser DE.

J Immunol. 2007 Mar 15;178(6):3566-74.

36.

Full activation of the T cell receptor requires both clustering and conformational changes at CD3.

Minguet S, Swamy M, Alarcón B, Luescher IF, Schamel WW.

Immunity. 2007 Jan;26(1):43-54. Epub 2006 Dec 21.

37.

Fluorescence-activated cell sorting and cloning of bona fide CD8+ CTL with reversible MHC-peptide and antibody Fab' conjugates.

Guillaume P, Baumgaertner P, Angelov GS, Speiser D, Luescher IF.

J Immunol. 2006 Sep 15;177(6):3903-12.

38.

Soluble MHC-peptide complexes containing long rigid linkers abolish CTL-mediated cytotoxicity.

Angelov GS, Guillaume P, Cebecauer M, Bosshard G, Dojcinovic D, Baumgaertner P, Luescher IF.

J Immunol. 2006 Mar 15;176(6):3356-65.

39.

CD8 kinetically promotes ligand binding to the T-cell antigen receptor.

Gakamsky DM, Luescher IF, Pramanik A, Kopito RB, Lemonnier F, Vogel H, Rigler R, Pecht I.

Biophys J. 2005 Sep;89(3):2121-33. Epub 2005 Jun 24.

40.

Soluble MHC-peptide complexes induce rapid death of CD8+ CTL.

Cebecauer M, Guillaume P, Hozák P, Mark S, Everett H, Schneider P, Luescher IF.

J Immunol. 2005 Jun 1;174(11):6809-19.

41.

CD8+ cytotoxic T lymphocyte activation by soluble major histocompatibility complex-peptide dimers.

Cebecauer M, Guillaume P, Mark S, Michielin O, Boucheron N, Bezard M, Meyer BH, Segura JM, Vogel H, Luescher IF.

J Biol Chem. 2005 Jun 24;280(25):23820-8. Epub 2005 Mar 31.

42.

Recent advances in tumour antigen-specific therapy: in vivo veritas.

Mahnke YD, Speiser D, Luescher IF, Cerottini JC, Romero P.

Int J Cancer. 2005 Jan 10;113(2):173-8. Review.

43.

T cell receptor-ligand interactions: a conformational preequilibrium or an induced fit.

Gakamsky DM, Luescher IF, Pecht I.

Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9063-6. Epub 2004 Jun 3.

44.

Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.

Speiser DE, Pittet MJ, Rimoldi D, Guillaume P, Luescher IF, Liénard D, Lejeune F, Cerottini JC, Romero P.

Semin Cancer Biol. 2003 Dec;13(6):461-72. Review.

PMID:
15001165
45.

Cis association of Ly49A with MHC class I restricts natural killer cell inhibition.

Doucey MA, Scarpellino L, Zimmer J, Guillaume P, Luescher IF, Bron C, Held W.

Nat Immunol. 2004 Mar;5(3):328-36. Epub 2004 Feb 15.

PMID:
14973437
46.
47.

The beta1 and beta3 integrins promote T cell receptor-mediated cytotoxic T lymphocyte activation.

Doucey MA, Legler DF, Faroudi M, Boucheron N, Baumgaertner P, Naeher D, Cebecauer M, Hudrisier D, Rüegg C, Palmer E, Valitutti S, Bron C, Luescher IF.

J Biol Chem. 2003 Jul 18;278(29):26983-91. Epub 2003 Apr 10.

48.

Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.

Romero P, Valmori D, Pittet MJ, Zippelius A, Rimoldi D, Lévy F, Dutoit V, Ayyoub M, Rubio-Godoy V, Michielin O, Guillaume P, Batard P, Luescher IF, Lejeune F, Liénard D, Rufer N, Dietrich PY, Speiser DE, Cerottini JC.

Immunol Rev. 2002 Oct;188:81-96. Review.

PMID:
12445283
49.

Soluble major histocompatibility complex-peptide octamers with impaired CD8 binding selectively induce Fas-dependent apoptosis.

Guillaume P, Legler DF, Boucheron N, Doucey MA, Cerottini JC, Luescher IF.

J Biol Chem. 2003 Feb 14;278(7):4500-9. Epub 2002 Oct 28.

50.

A role for the alpha-chain connecting peptide motif in mediating TCR-CD8 cooperation.

Naeher D, Luescher IF, Palmer E.

J Immunol. 2002 Sep 15;169(6):2964-70.

Supplemental Content

Loading ...
Support Center